-
Nov 2014
Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development.
PLoS OneChow IT, Yang J, Gates TJ, James EA, Mai DT, Greenbaum CJ, Kwok WW -
Nov 2014
Molecular signatures differentiate immune states in type 1 diabetic families.
DiabetesChen YG, Cabrera SM, Jia S, Kaldunski ML, Kramer J, Cheong S, Geoffrey R, Roethle MF, Woodliff JE, Greenbaum CJ, Wang X, Hessner MJ -
Oct 2014
Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes.
Proc Natl Acad Sci U S AYang J, Chow IT, Sosinowski T, Torres-Chinn N, Greenbaum CJ, James EA, Kappler JW, Davidson HW, Kwok WW -
Sep 2014
Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes.
DiabetesMcGinty JW, Chow IT, Greenbaum CJ, Odegard JM, Kwok WW, James EA -
Aug 2014
Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr.
Pediatr DiabetesMax Andersen ML, Nielsen LB, Svensson J, Pörksen S, Hougaard P, Beam C, Greenbaum CJ, Becker D, Petersen JS, Hansen L, Mortensen HB -
May 2014
Avidity-dependent programming of autoreactive T cells in T1D.
PLoS OneDurinovic-Belló I, Gersuk VH, Ni C, Wu R, Thorpe J, Jospe N, Sanda S, Greenbaum CJ, Nepom GT -
May 2014
Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease.
Physiol RepAfkarian M, Hirsch IB, Tuttle KR, Greenbaum CJ, Himmelfarb J, de Boer IH -
May 2014
Low HERV-K(C4) copy number is associated with type 1 diabetes.
DiabetesMason MJ, Speake C, Gersuk VH, Nguyen QA, O'Brien KK, Odegard JM, Buckner JH, Greenbaum CJ, Chaussabel D, Nepom GT -
Apr 2014
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.
Diabetes CareSosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. -
Apr 2014
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Diabetes CareOrban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. -
Mar 2014
Residual C-peptide in type 1 diabetes: what do we really know?
Pediatr DiabetesVanBuecken DE, Greenbaum CJ -
Feb 2014
B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Diabetes CarePescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group. -
Dec 2013
Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.
PLoS OneCerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum CJ, Kita M, Buckner JH, Long SA -
Dec 2013
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
DiabetesSosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. -
Dec 2013
IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Clin ImmunolLong SA, Buckner JH, Greenbaum CJ
